A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2011
12/22/2011	US20110312993 Amido-tropane derivatives
12/22/2011	US20110312991 Activated blood coagulation factor inhibitor
12/22/2011	US20110312989 Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
12/22/2011	US20110312984 Stat3 inhibitors
12/22/2011	US20110312979 Fused pyrrole derivatives as pi3k inhibitors
12/22/2011	US20110312975 Certain chemical entities, compositions and methods
12/22/2011	US20110312971 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/22/2011	US20110312964 Cysteine protease inhibitors
12/22/2011	US20110312962 Novel 2-morpholino-3-amido-pyridine derivatives and their medical use
12/22/2011	US20110312961 2,5-Disubstituted Morpholine Orexin REceptor Antagonists
12/22/2011	US20110312960 Pyrazine derivatives and use as pi3k inhibitors
12/22/2011	US20110312958 Modulators of atp-binding cassette transporters
12/22/2011	US20110312956 ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING
12/22/2011	US20110312951 C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof
12/22/2011	US20110312950 CYCLIC INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
12/22/2011	US20110312948 Crystalline Forms of the Tri-Mesylate Salt of Perphenazine-Gaba and Process of Producing the Same
12/22/2011	US20110312944 Heterocyclic Compounds Which Modulate The CB2 Receptor
12/22/2011	US20110312941 1,4-disubstituted piperidines as vasopressin receptor via antagonists
12/22/2011	US20110312938 Pyrrolopyridine Carboxylic Acid Derivatives
12/22/2011	US20110312937 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
12/22/2011	US20110312936 Cyclohexyl-azetidinyl antagonists of ccr2
12/22/2011	US20110312935 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents
12/22/2011	US20110312934 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine derivatives, preparation thereof, and therapeutic application thereof
12/22/2011	US20110312932 Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor
12/22/2011	US20110312931 Glycine transporter-1 inhibitors, methods of making them, and uses thereof
12/22/2011	US20110312930 Aryl compounds with aminoalkyl substituents and their use
12/22/2011	US20110312925 Methods of treating or preventing estrogen-related diseases
12/22/2011	US20110312921 N-Myristoyl Transferase Inhibitors
12/22/2011	US20110312920 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same
12/22/2011	US20110312913 Method and pharmaceutical to treat spinal discs
12/22/2011	US20110312912 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
12/22/2011	US20110312905 Stimulus-triggered prodrugs
12/22/2011	US20110312904 Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
12/22/2011	US20110312900 BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE
12/22/2011	US20110312895 Dipeptide mimetics of ngf and bdnf neurotrophins
12/22/2011	US20110312894 Methods of diagnosing and treating neurodegenerative diseases
12/22/2011	US20110312893 Method for isolating neural cells with tenascin-r compounds
12/22/2011	US20110312892 Anxiolytic compositions containing alpha s1-casein-derived peptides
12/22/2011	US20110312883 Neurturin molecules
12/22/2011	US20110312881 Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
12/22/2011	US20110312878 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
12/22/2011	US20110312873 N-terminally modified tetrapeptide derivatives having a c-terminal arginine mimetic
12/22/2011	US20110312093 Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
12/22/2011	US20110311657 Use of a Neuroprotective Extract and Pharmaceutical Preparation Thereof
12/22/2011	US20110311654 Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders
12/22/2011	US20110311652 Novel Saponin Compounds, Methods of Preparation Thereof, Use Thereof and Pharmaceutical Compositions
12/22/2011	US20110311626 Controlled release compositions comprising anti-cholinergic drugs
12/22/2011	US20110311562 Glycolipid Mixture with Anti-Inflammatory Activity Obtained from Oscillatoria Planktothrix
12/22/2011	US20110311542 Sp35 Antibodies and Uses Thereof
12/22/2011	US20110311531 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/22/2011	US20110311521 Novel therapy for anxiety
12/22/2011	US20110311517 Antibodies and methods for treating estrogen receptor-associated diseases
12/22/2011	US20110311512 Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets
12/22/2011	US20110311507 Methods for Diagnosing and Treating Autoimmune Disorders
12/22/2011	US20110311498 Generation of patient-specific differentiated cell types by epigenetic induction
12/22/2011	US20110311491 Treatment of sarcoidosis using placental stem cells
12/22/2011	US20110311489 Optically-based stimulation of target cells and modifications thereto
12/22/2011	US20110311486 1,2,4-oxadiazole benzoic acid compositions
12/22/2011	US20110311485 1,2,4-oxadiazole derivatives and their therapeutic use
12/22/2011	US20110311483 Crth2 modulators
12/22/2011	US20110311479 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
12/22/2011	US20110311474 Novel Tricyclic Compounds
12/22/2011	US20110311473 Methods of treating cognitive impairment
12/22/2011	US20110311451 Synthesis of polymer conjugates of indolocarbazole compounds
12/22/2011	US20110311447 Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand
12/22/2011	CA2802990A1 Asenapine maleate
12/22/2011	CA2802957A1 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
12/22/2011	CA2802441A1 Use of isoacteoside or pharmaceutically acceptable salt thereof
12/22/2011	CA2801581A1 Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders
12/22/2011	CA2801281A1 Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
12/21/2011	EP2397494A1 Human antibodies that bind human TNFalpha
12/21/2011	EP2397488A1 Dipeptide mimetics of ngf and bdnf neurotrophins
12/21/2011	EP2397481A1 Inhibitor of casein kinase 1delta and casein kinase 1epsilon
12/21/2011	EP2397480A1 Diazepinedione derivative
12/21/2011	EP2397477A1 Heterocyclic-substituted piperidine compounds and the uses thereof
12/21/2011	EP2397159A2 Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain
12/21/2011	EP2397158A2 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
12/21/2011	EP2397144A1 Use of Isoacteoside in Preventing or Treating Amyloid Beta Peptide-Associated Diseases or Conditions, and Method for Inhibiting Formation, Accumulation or Aggregation of Amyloid Beta Peptides
12/21/2011	EP2397143A1 Freeze-dried preparation of tetrodotoxin and the producing method thereof
12/21/2011	EP2397139A1 Anti-neurodegenerative disease agent
12/21/2011	EP2397137A1 Use of inverse antagonists and/or agonists of cb1 receptors for preparing drugs to increase motor neurone excitability
12/21/2011	EP2397126A1 Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses
12/21/2011	EP2396335A1 N-[(6-azabicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof
12/21/2011	EP2396334A1 N-[(2-azabicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof
12/21/2011	EP2396327A1 Histamine h3 inverse agonists and antagonists and methods of use thereof
12/21/2011	EP2396323A1 Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
12/21/2011	EP2396316A1 Quinazolinones as prolyl hydroxylase inhibitors
12/21/2011	EP2396305A1 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione
12/21/2011	EP2396296A1 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
12/21/2011	EP2396295A1 Phenoxy acetic acid derivatives
12/21/2011	EP2396083A2 Products comprising n-phenylpropenoyl amino acid amides and uses thereof
12/21/2011	EP2396038A2 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
12/21/2011	EP2396027A2 Combined treatment of multiple sclerosis
12/21/2011	EP2396016A1 Neuroactive plant extract from hypericum polyanthemum
12/21/2011	EP2396002A2 (2.2.2) bicyclic derivatives and methods of use
12/21/2011	EP2395990A1 Material and methods for treating developmental disorders including comorbid and idiopathic autism
12/21/2011	EP2321295B1 4-(pyridin-4-yl)-1h-[1,3,5]triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
12/21/2011	EP2219647B1 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
12/21/2011	EP2211850B1 A system and method to improve sensory function
12/21/2011	EP2155736B1 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

1 ... 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 ... 1833